[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639457":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":42,"collaborators":46,"id":53,"slug":7,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":7,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":7,"overallStatus":71,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Stanford University","OTHER",null,[9,27],{"facility":10,"status":7,"city":11,"state":12,"zip":13,"country":14,"cosmosGeoPoint":15,"geoPoint":20,"contacts":21},"Stanford University Hypertension Center","Palo Alto","California","94304","United States",{"type":16,"coordinates":17},"Point",[18,19],-122.14302,37.44188,{"lat":19,"lon":18},[22],{"name":23,"role":24,"phone":25,"phoneExt":7,"email":26},"Joel Nicholus, MA","CONTACT","650-947-7025","nicholus@stanford.edu",{"facility":28,"status":7,"city":29,"state":30,"zip":31,"country":14,"cosmosGeoPoint":32,"geoPoint":36,"contacts":37},"Duke University Hospital","Durham","North Carolina","27710",{"type":16,"coordinates":33},[34,35],-78.89862,35.99403,{"lat":35,"lon":34},[38],{"name":39,"role":24,"phone":40,"phoneExt":7,"email":41},"Krista Camuglia, BSN","919-862-5967","krista.camuglia@duke.edu",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Vivek Bhalla","Associate Professor of Medicine (Nephrology)",[47,50],{"name":48,"class":49},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",{"name":51,"class":52},"Duke University Medical Center, Durham, NC","UNKNOWN","100639457",false,"NCT07579260","IMPACT-HTN Study of Patients With Hypertension","Prospective Early Patient Experience Initiative (IMPACT-HTN)","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Ability to answer survey questions and to report blood pressure reading monthly\n* Male and female participants; 18 years or older\n* Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit\n* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg\n\nExclusion Criteria:\n\n* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and\u002For Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg\n* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator\n* Heart failure NYHA functional class III and IV or NT-proBNP \\> 500 pg\u002FmL\n* Severe renal insufficiency or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2\n* Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\\> 3 x ULN)","ALL","18 Years",{"count":62,"type":63},100,"ESTIMATED","97 Days","OBSERVATIONAL","An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.",[68,69,70],"Hypertension (HTN)","Hypertension","Blood Pressure, High","NOT_YET_RECRUITING","2026-06-24",{"date":74,"type":75},"2026-06-29","ACTUAL",{"date":77,"type":63},"2026-07-01",{"date":79,"type":63},"2027-04-01",{"name":44,"class":6},2]